Why IOVA fell 20.1% on Oct 29 2026: phase 2 data update
IOVA-20.1%on Thu Oct 29 2026
Iovance Biotherapeutics, Inc. Common Stock was down 20.1% on the day at $11.83, ranked #5 on 179× its usual five-minute volume, when TapeRank recorded this drop at 07:46 ET during the pre-market session. TapeRank recorded 2 events for IOVA that day, between 04:32 and 07:46 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 04:32 ETUNEXPLAINED MOVE · PRE-MARKET
$17.25 · ▲ 16.5% ON THE DAY · 5.4× 5M RVOL · RANK #1
UNEXPLAINEDNO FILINGS · RULEIOVA is up 11.3% on the day on 4.3x its normal volume for this time of day. No filings or headlines were found in SEC EDGAR filings and Benzinga wire headlines in the last 24 hours, so this is order flow rather than a disclosed catalyst.
WHYNo filings or headlines within 24 hours of the move.ANALYZED 04:19 ET · 13 MIN AGO · RULE, NO MODELTHE ROW AND SESSION LEVELS AT 04:32 ET
LAST17.25DAY▲ 16.5%5 MIN▲ 3.48%5M RVOL5.4×5M $VOL$124KFLOAT*453.0MRANK#1SESSIONPRE-MARKETVWAP16.57HOD17.06LOD16.31OR HIGH—OR LOW—PREV CLOSE14.81PM HIGH17.06PM LOW16.31GAP▲ 13.44% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 07:46 ETMOVER · PRE-MARKET
$11.83 · ▼ 20.1% ON THE DAY · 179× 5M RVOL · RANK #5
STRETCHEDCONFIDENCE4/5Iovance is down 11.9% pre-market after updated Phase 2 lung-cancer data showed a 24.6% objective response rate, consistent with previously reported results. The planned 2027 supplemental filing and future biomarker-enriched study are incremental, so the sharp selloff is larger than this largely reaffirming update supports.
WHYA 11.9% decline is outsized relative to data that were consistent with prior results and included only a planned 2027 filing and future study.ANALYZED 07:42 ET · 3 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 07:46 ET
LAST11.83DAY▼ 20.1%5 MIN▼ 8.79%5M RVOL179×5M $VOL$3.8MFLOAT*453.0MRANK#5SESSIONPRE-MARKETVWAP13.90HOD17.25LOD11.91OR HIGH—OR LOW—PREV CLOSE14.81PM HIGH17.25PM LOW11.91GAP▼ 19.31% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $10.70, -27.8% on the previous close of $14.81
- 09:37 ETRegular-session high, $11.58
- 11:10 ETRegular-session low, $9.35
- 15:59 ETLast trade of the regular session, $9.55, -35.5% on the previous close of $14.81
- Volume: 46.1M shares in regular hours, 10.7M before the open
IOVA opened at $10.70, briefly reached $11.58, then fell to $9.35 by 11:10 ET before ending the regular session at $9.55, down 35.5% from the previous close. TapeRank tied the premarket selloff to Iovance’s updated Phase 2 lung-cancer data, which showed a 24.6% objective response rate consistent with previously reported results, along with a planned 2027 filing and future study; it judged the decline stretched relative to that update. TapeRank also recorded an earlier unexplained move because no filings or headlines within 24 hours explained it, and no halts occurred.
WRITTEN THU OCT 29 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list